AGMT Austrian Lymphoma Registry

NCT06294652 | Recruiting

• 1 other identifier: AGMT_Lymphoma_Reg
• Study Type: observational
• Target: 4,000
• Locations: 1 country
• Sites: 1

Brief Summary

Lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). There are different subtypes of HL, including classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. Non-Hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with distinct genetic, molecular, and clinical features. Common subtypes of NHL include Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL), myeloma, and other rarer subgroups. Many of these diseases typically present with lymph node enlargement, bone marrow infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities. Novel agents have improved the prognosis of high-risk lymphoma patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis. Lymphoma disease have not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. As lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. Which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus.

Conditions

Lymphoma

Keywords

Lymphoma; Diffuse large B-cel lymphoma (DLBCL)

Outcome Measures

Primary Outcomes (8)

• General Characteristics

  To describe general characteristics of lymphoma patients

  10 years

• Genetic Profiling

  To describe genetic risk profiles

  10 years

• Proportion of lymphoma patients in Austria that require treatment

  To describe the proportion of lymphoma patients in Austria that require treatment

  10 years

• Proportion of lymphoma patients in Austria under active surveillance

  To describe the proportion of lymphoma patients in Austria under active surveillance

  10 years

• Number of patients with concomitant diseases

  To describe concomitant diseases at diagnosis of lymphoma

  10 years

• Number of treatment and outcome of treatment

  To describe treatment and outcome of treatment, among them * historical standard with immunochemotherapy * cellular therapies (e.g. Car-T cells) * novel immunotherapies such as bispecific antibodies * continuous treatment or an induction/maintenance approach * sequence of use of various treatments * treatment duration * treatment adjustments * frequency and degree of response

  10 years

• Patient Outcome

  To describe patient's outcome

  10 years

• Toxicities

  To describe toxicity with a focus on immunological mediated side effects of treatment (e.g. Cytokine release syndrome (CRS), Immune effector cell-associated neurotoxicity syndrome (ICAN) etc.)

  10 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Interested sites that treat patients in this indication will be invited to participate in this registry.

You may qualify if:

• The registry will include patients ≥ 18 years with lymphoma.

Sponsors & Collaborators

• Arbeitsgemeinschaft medikamentoese Tumortherapie: lead

Study Sites (1)

Universitätsklinik für Innere Medizin III, PMU Salzburg

Salzburg, Salzburg, 5020, Austria

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

The Lymphoma registry will be accompanied by an optional biobanking program. Sample collection will be limited to patients that have signed an additional biobanking IC. The samples are taken as part of the clinical routine.

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Richard Greil, MD

  Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Daniela Wolkersdorfer, Dr.

CONTACT

+436626404412; office@agmt.at

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2024
• First Posted: March 5, 2024
• Study Start: February 27, 2024
• Primary Completion (Estimated): December 31, 2033
• Study Completion (Estimated): December 31, 2033
• Last Updated: April 10, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)